JP2023501789A - 補体成分Ｃ５ａ受容体の非晶質形態 - Google Patents

補体成分Ｃ５ａ受容体の非晶質形態 Download PDF

Info

Publication number
JP2023501789A
JP2023501789A JP2022525877A JP2022525877A JP2023501789A JP 2023501789 A JP2023501789 A JP 2023501789A JP 2022525877 A JP2022525877 A JP 2022525877A JP 2022525877 A JP2022525877 A JP 2022525877A JP 2023501789 A JP2023501789 A JP 2023501789A
Authority
JP
Japan
Prior art keywords
compound
amorphous form
disease
disorder
amorphous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022525877A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501789A5 (https=
Inventor
ヤウ クウォク
ルオン ケンケン
シン ラジンダー
イーピン ツォン
ジャーン ペングリー
レディー レレティ マンモハン
エム．ルイ レベッカ
Original Assignee
ケモセントリックス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75846408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2023501789(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ケモセントリックス，インコーポレイティド filed Critical ケモセントリックス，インコーポレイティド
Publication of JP2023501789A publication Critical patent/JP2023501789A/ja
Publication of JP2023501789A5 publication Critical patent/JP2023501789A5/ja
Priority to JP2025171004A priority Critical patent/JP2026016449A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Secondary Cells (AREA)
  • Soft Magnetic Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022525877A 2019-11-08 2020-11-06 補体成分Ｃ５ａ受容体の非晶質形態 Pending JP2023501789A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025171004A JP2026016449A (ja) 2019-11-08 2025-10-09 補体成分Ｃ５ａ受容体の非晶質形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962932644P 2019-11-08 2019-11-08
US62/932,644 2019-11-08
PCT/US2020/059280 WO2021092286A1 (en) 2019-11-08 2020-11-06 Amorphous form of a complement component c5a receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025171004A Division JP2026016449A (ja) 2019-11-08 2025-10-09 補体成分Ｃ５ａ受容体の非晶質形態

Publications (2)

Publication Number Publication Date
JP2023501789A true JP2023501789A (ja) 2023-01-19
JP2023501789A5 JP2023501789A5 (https=) 2023-11-10

Family

ID=75846408

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525877A Pending JP2023501789A (ja) 2019-11-08 2020-11-06 補体成分Ｃ５ａ受容体の非晶質形態
JP2025171004A Pending JP2026016449A (ja) 2019-11-08 2025-10-09 補体成分Ｃ５ａ受容体の非晶質形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025171004A Pending JP2026016449A (ja) 2019-11-08 2025-10-09 補体成分Ｃ５ａ受容体の非晶質形態

Country Status (13)

Country Link
US (1) US11603356B2 (https=)
EP (1) EP4054576A4 (https=)
JP (2) JP2023501789A (https=)
KR (1) KR20220098754A (https=)
CN (1) CN114641288A (https=)
AU (1) AU2020378397A1 (https=)
BR (1) BR112022007489A2 (https=)
CA (1) CA3155542A1 (https=)
CL (1) CL2022001172A1 (https=)
IL (1) IL292383A (https=)
MX (1) MX2022005406A (https=)
WO (1) WO2021092286A1 (https=)
ZA (1) ZA202305624B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114867473A (zh) 2019-11-08 2022-08-05 凯莫森特里克斯股份有限公司 补体成分c5a受体的盐形式
US11603356B2 (en) 2019-11-08 2023-03-14 Chemocentryx, Inc. Amorphous form of a complement component C5a receptor
WO2022078269A1 (zh) * 2020-10-16 2022-04-21 苏州科睿思制药有限公司 Avacopan的晶型及其制备方法和用途
EP4137133A1 (en) 2021-08-19 2023-02-22 Sandoz AG Crystalline form of avacopan
WO2022263263A1 (en) 2021-06-16 2022-12-22 Sandoz Ag Crystalline form of avacopan
US20250333381A1 (en) 2024-04-26 2025-10-30 Amgen Inc. Solid state forms
US20260027049A1 (en) 2024-07-23 2026-01-29 Amgen Inc. Avacopan formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012513402A (ja) * 2008-12-22 2012-06-14 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト
JP2013529647A (ja) * 2010-06-24 2013-07-22 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト
JP2017529378A (ja) * 2014-09-29 2017-10-05 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト製造における方法及び中間体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4996467B2 (ja) * 2004-09-27 2012-08-08 アカディア ファーマシューティカルズ インコーポレイテッド Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミド、並びにその酒石酸塩及び結晶形態の合成
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
CA3078732A1 (en) 2017-10-31 2019-05-09 Chemocentryx, Inc. C5ar inhibitor reduction of urinary scd163
US11191756B2 (en) 2018-06-07 2021-12-07 Chemocentryx, Inc. Dosing and effect of C5a antagonist with ANCA-associated vasculitis
WO2020112961A1 (en) 2018-11-30 2020-06-04 Chemocentryx, Inc. Capsule formulations
IL312955B1 (en) 2019-03-11 2026-01-01 Inflarx Gmbh Fused piperidinyl bicyclic compounds and related compounds as C5a receptor modulators
CN114867473A (zh) 2019-11-08 2022-08-05 凯莫森特里克斯股份有限公司 补体成分c5a受体的盐形式
US11603356B2 (en) 2019-11-08 2023-03-14 Chemocentryx, Inc. Amorphous form of a complement component C5a receptor
JP2022554019A (ja) 2019-11-08 2022-12-27 ケモセントリックス，インコーポレイティド 補体成分Ｃ５ａ受容体の遊離塩基結晶形態
WO2022078269A1 (zh) 2020-10-16 2022-04-21 苏州科睿思制药有限公司 Avacopan的晶型及其制备方法和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012513402A (ja) * 2008-12-22 2012-06-14 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト
JP2013529647A (ja) * 2010-06-24 2013-07-22 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト
JP2017529378A (ja) * 2014-09-29 2017-10-05 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト製造における方法及び中間体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
森部久仁一 ほか: "非晶質医薬品の調製と評価", 低温生物工学会誌, vol. 51, no. 1, JPN6020003904, 2005, pages 19 - 24, ISSN: 0005438262 *
米持悦生: "医薬品原薬及び製剤のバルク状態分析の重要性", SCAS NEWS, vol. 2004-II, JPN6017004374, 2004, pages 3 - 6, ISSN: 0005438261 *

Also Published As

Publication number Publication date
TW202128622A (zh) 2021-08-01
US20210139426A1 (en) 2021-05-13
US11603356B2 (en) 2023-03-14
ZA202305624B (en) 2023-12-20
BR112022007489A2 (pt) 2022-07-12
CL2022001172A1 (es) 2023-02-17
KR20220098754A (ko) 2022-07-12
MX2022005406A (es) 2022-05-24
WO2021092286A1 (en) 2021-05-14
EP4054576A4 (en) 2023-12-13
JP2026016449A (ja) 2026-02-03
CN114641288A (zh) 2022-06-17
AU2020378397A1 (en) 2022-06-23
EP4054576A1 (en) 2022-09-14
IL292383A (en) 2022-06-01
CA3155542A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
US11603356B2 (en) Amorphous form of a complement component C5a receptor
US20230381167A1 (en) FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR
TWI900501B (zh) 補體成分Ｃ５ａ受體之鹽形式
RU2859662C2 (ru) АМОРФНАЯ ФОРМА КОМПОНЕНТА КОМПЛЕМЕНТА РЕЦЕПТОРА C5a
TWI921314B (zh) 補體成份C5a受體之非晶型
RU2859117C1 (ru) СОЛЕВЫЕ ФОРМЫ КОМПОНЕНТА КОМПЛЕМЕНТА РЕЦЕПТОРА C5a

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250414

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251118